Tandem Diabetes Care Inc. (NASDAQ:TNDM)’s share price shot up 3.9% on Monday . The stock traded as high as $7.01 and last traded at $6.91, with a volume of 119,852 shares traded. The stock had previously closed at $6.65.

Several research firms recently weighed in on TNDM. Zacks Investment Research downgraded Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research report on Wednesday, August 3rd. Wedbush reiterated an “outperform” rating and set a $20.00 target price on shares of Tandem Diabetes Care in a research report on Friday, July 29th. Sterne Agee CRT reiterated a “neutral” rating on shares of Tandem Diabetes Care in a research report on Monday, May 16th. Finally, Robert W. Baird reiterated a “buy” rating on shares of Tandem Diabetes Care in a research report on Monday, May 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $14.21.

The stock’s market capitalization is $214.60 million. The company has a 50 day moving average of $7.18 and a 200 day moving average of $7.97.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings results on Thursday, July 28th. The medical device company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.05. The firm had revenue of $23 million for the quarter, compared to analyst estimates of $23.08 million. The firm’s revenue for the quarter was up 46.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.65) earnings per share. Equities research analysts anticipate that Tandem Diabetes Care Inc. will post ($2.14) EPS for the current fiscal year.

In other news, EVP John F. Sheridan sold 15,000 shares of Tandem Diabetes Care stock in a transaction on Monday, August 1st. The stock was sold at an average price of $6.52, for a total transaction of $97,800.00. Following the transaction, the executive vice president now directly owns 22,763 shares in the company, valued at approximately $148,414.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.